Assembly Biosciences (ASMB) shares were higher Wednesday morning after the company said that a first subject has been dosed in the phase 1a trial of ABI-6250, its hepatitis delta virus entry inhibitor candidate.
The study aims to evaluate the safety, tolerability and pharmacokinetics of the therapy across single and multiple ascending dose cohorts in participants. The study will also look at serum bile acids as a biomarker of ABI-6250's engagement of its target, which is the transporter used by the disease to infect hepatocyte.
The company said it expects to share data from the study in Q3.
Price: 12.90, Change: +0.56, Percent Change: +4.54
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。